SCHEMBL18758568

SCHEMBL18758568

COC(=O)c1ccc([C@H](C)NC(=O)c2c(C(F)(F)F)nn3c2N(Cc2ccc(C(F)(F)F)cc2)CCC3)cc1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 19/20 0.48
▸ PTGER2 P43116 1/20 0.42
▸ PDE2A O00408 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28616118 1.00 PTGER4 (0.48) PTGER4PTGER2PDE2A
SCHEMBL28627341 0.95 PTGER4 (0.49) PTGER4PTGER2
SCHEMBL18758745 0.95 PTGER4 (0.49) PTGER4PTGER2
SCHEMBL18758446 0.94 PTGER4 (0.43) PTGER4PTGER2
SCHEMBL28634874 0.94 PTGER4 (0.43) PTGER4PTGER2
SCHEMBL18740045 0.92 PTGER4 (0.58) PTGER4PTGER2
SCHEMBL18740042 0.92 PTGER4 (0.58) PTGER4PTGER2
SCHEMBL29893455 0.91 PTGER4 (0.51) PTGER4PTGER2
SCHEMBL28922414 0.91 PTGER4 (0.51) PTGER4PTGER2
SCHEMBL21081538 0.91 PTGER4 (0.51) PTGER4PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885PTGER2 4/4885PDE2A 265/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885PTGER2 4/4885PDE2A 265/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885PTGER2 4/4885PDE2A 265/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 PTGER4 1/4885PTGER2 4/4885PDE2A 265/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 PTGER4 1/4885PTGER2 4/4885PDE2A 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback